Mylan (MYL) has been in the hot seat since reports of its extravagant price hikes for the EpiPen, a device which millions of Americans, including 1 in 13 children, rely on as a life-saving backstop, emerged last month.
Click here to subscribe to our upcoming Brainstorm Health Daily Newsletter.
Several members of Congress have been demanding more information from the generic drug giant about its pricing practices since the EpiPen scandal broke. Some, including Minnesota Sen. Amy Klobuchar, have even called for Federal Trade Commission (FTC) investigations into the company.
The U.S. House Committee on Oversight and Government Reform specifically asked for more detailed information about Mylan’s pricing habits, including discounts given to patients, at the end of August. The firm was asked to submit the documentation by the end of Monday.
See also: Don’t Only Blame Mylan for $600 EpiPens
That information is expected to reach lawmakers by the end of the week, according to CNN.
Mylan has been forced to offer steeper customer discounts for the EpiPen in the midst of tumbling share prices and has even gone so far as to announce it will release a generic competitor to its own product to lower customers’ costs. The firm’s shares are down 29% year-to-date.